Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.
作者信息
Merone Lea, Finlay Summer
机构信息
Apunipima Cape York Health Council, Queensland.
Division of Tropical Health and Medicine, James Cook University, Queensland.
出版信息
Aust N Z J Public Health. 2020 Dec;44(6):437-439. doi: 10.1111/1753-6405.13044. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.大流行与希望：在寻找新型冠状病毒19有效治疗方法方面取得的进展。
Aust N Z J Public Health. 2020 Dec;44(6):437-439. doi: 10.1111/1753-6405.13044. Epub 2020 Oct 12.
2
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
3
Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.关于将伊维菌素重新用于治疗新冠肺炎的药代动力学考量
Br J Clin Pharmacol. 2021 Mar;87(3):1589-1590. doi: 10.1111/bcp.14476. Epub 2020 Jul 17.
4
From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?从羟氯喹到伊维菌素：抗寄生虫药物的抗病毒特性如何对抗 SARS-CoV-2？
J Travel Med. 2021 Feb 23;28(2). doi: 10.1093/jtm/taab005.
5
Possible treatment and strategies for COVID-19: review and assessment.针对 COVID-19 的可能治疗方法和策略：综述与评估。
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057.
6
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?广谱宿主导向药物伊维菌素作为 SARS-CoV-2 的抗病毒药物？
Biochem Biophys Res Commun. 2021 Jan 29;538:163-172. doi: 10.1016/j.bbrc.2020.10.042. Epub 2020 Oct 21.
7
Ivermectin for preventing and treating COVID-19.伊维菌素预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2.
8
Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in COVID-19.伊维菌素的抗病毒和抗炎特性及其在COVID-19中的潜在用途
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):831. doi: 10.1016/j.arbres.2020.06.011. Epub 2020 Jul 7.
9
Ivermectin in COVID-19: What do we know?伊维菌素与新冠病毒：我们了解些什么？
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1921-1922. doi: 10.1016/j.dsx.2020.09.027. Epub 2020 Sep 28.
10
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.重新定位伊维菌素治疗新冠病毒：针对 SARS-CoV-2 复制的分子作用机制。
Biochim Biophys Acta Mol Basis Dis. 2022 Feb 1;1868(2):166294. doi: 10.1016/j.bbadis.2021.166294. Epub 2021 Oct 20.
引用本文的文献
1
COVID-19: The Pseudo-Environment and the Need for a Paradigm Change.新冠病毒肺炎：拟态环境与范式转变的必要性
Germs. 2021 Dec 29;11(4):468-477. doi: 10.18683/germs.2021.1283. eCollection 2021 Dec.
本文引用的文献
1
Role for antimalarials in the management of COVID-19.抗疟药物在 COVID-19 管理中的作用。
Curr Opin Rheumatol. 2020 Sep;32(5):449-457. doi: 10.1097/BOR.0000000000000731.
2
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.羟氯喹治疗轻症 2019 年冠状病毒病成人患者的随机对照临床试验。
Clin Infect Dis. 2021 Dec 6;73(11):e4073-e4081. doi: 10.1093/cid/ciaa1009.
3
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
4
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 住院风险的相关性：一项基于病例的队列研究
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
5
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.洛匹那韦/利托那韦联合疗法用于印度有症状的 2019 冠状病毒病患者：限制公共卫生紧急使用的方案。
Indian J Med Res. 2020;151(2 & 3):184-189. doi: 10.4103/ijmr.IJMR_502_20.
6
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
7
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses.新型冠状病毒肺炎感染：人类冠状病毒的起源、传播及特征
J Adv Res. 2020 Mar 16;24:91-98. doi: 10.1016/j.jare.2020.03.005. eCollection 2020 Jul.
8
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?新型冠状病毒肺炎与非甾体抗炎药和皮质类固醇治疗：我们是否应在临床环境中限制其使用？
Ecancermedicalscience. 2020 Mar 30;14:1023. doi: 10.3332/ecancer.2020.1023. eCollection 2020.
9
Covid-19: NICE advises against using NSAIDs for fever in patients with suspected cases.新冠病毒-19：英国国家卫生与临床优化研究所建议，疑似病例患者发热时不要使用非甾体抗炎药。
BMJ. 2020 Apr 6;369:m1409. doi: 10.1136/bmj.m1409.
10
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
Zotero 插件